Finally, a five-year period for NS is likely not capturing the full story of survival for BC molecular subtypes, given that recurrence for TN and HER2+ BCs commonly occurs three to five years after diagnosis, and luminal A much longer than this. The gene discussed is ERBB2; the disease is breast cancer.